Bone Biologics (BBLG) Return on Capital Employed (2013 - 2025)
Bone Biologics (BBLG) reported Return on Capital Employed of 57.21% for Q4 2025, up 6045.0% year-over-year from 0.93% in Q4 2024, and up 10.57% quarter-over-quarter from 63.96% in Q3 2025.
Bone Biologics (BBLG) Return on Capital Employed (2013 - 2025) Analysis & Trends
Bone Biologics (BBLG) has 13 years of Return on Capital Employed data on file, last reported at 57.21% in Q4 2025.
- Return on Capital Employed for Q4 2025 came in at 57.21%, up 6045.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 57.21% (up 6045.0% YoY), and the FY2025 annual result was 73.35%, up 4995.0% from the prior year.
- Return on Capital Employed improved to 57.21% in Q4 2025 per BBLG's latest filing, from 63.96% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 33.8% in Q4 2021 and troughed at 267.42% in Q4 2023.
- A 5-year average of 131.18% and a median of 125.6% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed sank 18219 bps in 2023, then surged 14976 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 33.8% in 2021, then plunged by 152 bps to 85.23% in 2022, then sank by 214 bps to 267.42% in 2023, then soared by 56 bps to 117.66% in 2024, then soared by 51 bps to 57.21% in 2025.
- Business Quant data shows BBLG's Return on Capital Employed at 57.21% in Q4 2025, 63.96% in Q3 2025, and 91.8% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -107.40% |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -50.43% |
| 10 | Bone Biologics | 1.47 Mn | 1.47 Mn | - | -57.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -57.21% |
| Sep 30, 2025 | -63.96% |
| Jun 30, 2025 | -91.80% |
| Mar 31, 2025 | -133.54% |
| Dec 31, 2024 | -117.66% |
| Sep 30, 2024 | -113.94% |
| Jun 30, 2024 | -153.28% |
| Mar 31, 2024 | -198.24% |
| Dec 31, 2023 | -267.42% |
| Sep 30, 2023 | -186.76% |
| Jun 30, 2023 | -164.87% |
| Mar 31, 2023 | -168.77% |
| Dec 31, 2022 | -85.23% |
| Dec 31, 2021 | -33.80% |
| Sep 30, 2020 | 6.77% |
| Jun 30, 2020 | 8.19% |
| Mar 31, 2020 | 12.83% |
| Dec 31, 2019 | 558.31% |
| Sep 30, 2019 | 29.97% |
| Jun 30, 2019 | 25.54% |